NCT04347330

Cardiovascular Risk Reduction in Atrial Fibrillation Trial

Name: Clinical Trial NCT04347330
Creator: Beijing Anzhen Hospital
Keywords: Atrial Fibrillation,Hypertension, Intensive BP Control, drug, clinical trial, China

Beijing Anzhen Hospital·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Atrial Fibrillation,Hypertension
Drug/Device/Intervention: Intensive BP Control
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Beijing Anzhen Hospital
Location: Beijing, China

Timeline & enrollment

Phase: N/A
Start date: Aug 31, 2020
End date: Aug 01, 2025
Enrollment: 6000 participants

Primary outcome

Composite cardiovascular outcomes

Summary

Atrial fibrillation (AF) is a serious public health problem because of its increasing incidence and prevalence in the aging population. AF is associated with elevated risks of death, stroke, coronary event, heart failure, cognitive decline, and chronic kidney disease. To identify preventive interventions for major cardiovascular events beyond effective anticoagulation should be a major priority in the treatment of AF patients. The CRAFT study is a 2-arm, multicenter, randomized clinical trial designed to test whether intensive blood pressure control will reduce the risk of major cardiovascular events in AF patients.

ICD-10 classifications

Chronic atrial fibrillationPersistent atrial fibrillationParoxysmal atrial fibrillationAtrial fibrillation and flutterAtrial fibrillation and atrial flutter, unspecified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT04347330
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT04347330 through Pure Global AI's free database. This phase not specified trial is sponsored by Beijing Anzhen Hospital and is currently Recruiting. The study focuses on Atrial Fibrillation,Hypertension. Target enrollment is 6000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.